Antiplatelet therapy in acute coronary syndromes: Ticagrelor

Advances in Cardiology

Volumn 47, Issue , 2012, Pages 64-77

  Husted, Steen ^a  

^a REGIONAL HOSPITAL WEST JUTLAND   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; THIENOPYRIDINE DERIVATIVE; TICAGRELOR;

ACUTE CORONARY SYNDROME; ARTICLE; BLEEDING; CORONARY ARTERY BYPASS SURGERY; DRUG EFFICACY; HEART INFARCTION; HUMAN; LOADING DRUG DOSE; MORTALITY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; STROKE;

ADENOSINE; ANGIOPLASTY, BALLOON, CORONARY; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; MYOCARDIAL ISCHEMIA; PLATELET ACTIVATION; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RESEARCH DESIGN;

EID: 84865804346     PISSN: 00652326     EISSN: 16622839     Source Type: Book Series    
DOI: 10.1159/000338055     Document Type: Article

References (34)

1. 12 receptor antagonist. Cardio-vasc Ther 2009;27:259-274.
2. Gurbel PA, Bliden K P, Butler K, et al: Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 2009;120:2577-2585.
3. Teng R, Oliver S, Hayes MA, Butler K: Absorption, distribution, metabolism, and excretion of ticagre-lor in healthy subjects. Drug Metab Dispos 2010;38: 1514-1521.
4. 12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006;27:1038-1047.
5. Husted S: Unmet needs in oral antiplatelet therapy with ADP receptor blocking agents. Fundam Clin Pharmacol 2009;23:1-9.
6. Cannon CP, Husted S, Harrington RA, et al: Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol 2007;50:1844-1851.
7. Storey R F, Angiolillo DJ, Patil SBG, et al: Inhibitory effects of ticagrelor compared to clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy. J Am Coll Cardiol 2010;56:1456-1462.
8. Husted SE, Gurbel P, Storey RF, et al: Pharma-cokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease (abstract 5494). Circulation 2009;120:S1102.
9. James S, Åkerblom A, Cannon C P, et al: Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J 2009;157:599-605.
10. Wallentin L, Becker RC, Budaj A, et al: Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-1057.
11. King SB, Smith SC, Hirshfeld JW, Jacobs AK, Morrison DA, Williams DO: Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. Circulation 2008; 117:261-295.
12. Scirica BM, Cannon C P, Emanuelsson H: The incidence of bradyarrhythmias and clinical bradyar-rhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO Trial. Results of the Continuous Electrocardiographic Assessment substudy. J Am Coll Cardiol 2011;57:1908-1916.
13. Stenestrand U, Johansson S, Janzon M, Wallentin L: The Platelet Inhibition and Patient Outcomes trial (PLATO) is representative of patients with acute coronary syndromes in a National Heart Registry (abstract E1046). J Am Coll Cardiol 2010;55:A112.
14. 12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: results of the Platelet Inhibition and Patient Outcomes (PLATO) trial ESC, Barcelona, August 2009. http://www.escardio. org/congresses/esc-2009/congress-reports/Pages/706005-706006-wallentin- kristensen.aspx#discuss ant (accessed August 23, 2011).
15. Cannon CP, Harrington RA, James S, et al: Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet 2010;375:283-293.
16. James S, Roe M, Cannon C P, et al: Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management-a substudy from the prospective randomized Platelet Inhibition and Patient Outcomes (PLATO) trial. BMJ 2011;342:d3527.
17. Steg G, James S, Harrington RA, et al: Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary PCI; a Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation 2010;122:2131-2141.
18. James S, Angiolillo DJ, Cornel JH, et al: Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Eur Heart J 2010;31:3006-3016.
19. Held C, Åsenblad N, Bassand J-P, et al: Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery by-pass surgery: results from the PLATO trial. J Am Coll Cardiol 2011;57:672-684.
20. Mahaffey K W, Wojdyla DM, Carroll K, et al: Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation 2011;124:544-554.
21. 12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol 2007;50:1852-1856.
22. Rao S V, O'Grady K, Pieper KS, et al: A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes. J Am Coll Cardiol 2006;47: 809-816.
23. Storey RF, Becker RC, Harrington RA, et al: Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes. Eur Heart J 2011, E-pub ahead of print.
24. Storey R F, Bliden K P, Patil SB, et al: Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study. J Am Coll Cardiol 2010; 56:185-193.
25. Storey RF, Becker RC, Harrington RA, et al: Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel [from the Platelet Inhibition and Patient Outcomes (PLATO) pulmonary function substudy]. Am J Cardiol 2011;108:1542-1546.
26. AstraZeneca FDA advisory committee briefing document. 23 June 2010. Ticagrelor briefing document for cardiovascular and renal drugs advisory committee meeting NDA 22-433. http://www.fda. gov/downloads/AdvisoryCommittees/ Committees MeetingMaterials/Drugs/ardiovascularandRenal DrugsAdvisoryCommittee/ UCM220197.pdf (accessed August 23, 2011).
27. James SK, Budaj A, Aylward P, et al: Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function-results from the Platelet Inhibition And Patient Outcomes (PLATO) trial. Circulation 2010;122:1056-1067.
28. Husted S: Evidence-based prescribing and adherence to antiplatelet therapy-how much difference do they make to patients with atherothrombosis? Int J Cardiol 2009;134:150-159.
29. Wallentin L, James S, Storey R F, et al: Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 2010; 376:1320-1328.
30. Gurbel P, Bliden K, Antonino M, et al: Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation 2010;121:1188-1199.
31. Gurbel PA, Mahla E, Antonino MJ, et al: Response variability and the role of platelet function testing. J Invasive Cardiol 2009;21:172-178.
32. Bliden K P, Tantry US, Storey RF, et al: The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity: combined analysis of the ONSET/OFFSET and RESPOND studies. Am Heart J 2011;162:160-165.
33. TM, US full prescribing information, July 2011. http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/022433s0001b1.pdf (accessed September 27, 2011).
34. Janzon M, Nikolic E, Henriksson M, et al: Health economics in the Platelet Inhibition and Patient Outcomes (PLATO) randomized trial: report on within trial resource use patterns (abstract 17295). Circulation 2010;122.